drugset / Trial / NCT03333746
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Terminated
1 enrolled
Yvonne Efebera
American Cancer Society, Inc. · collabBristol-Myers Squibb · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well lenalidomide and nivolumab work in treating patients with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide and nivolumab may work better in treating patients with multiple myeloma.
Timeline
- Start
- 2018-03-21
- Primary completion
- 2018-08-13
- Completion
- 2018-11-16
Outcome
Outcome not reported
Stopped: “Study was discontinued due to FDA recommendations of the potential toxicities of the combination of drugs.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |